TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05667493
Drug: Eplontersen
Normalized name: EPLONTERSEN
DrugBank: Eplontersen (DB16199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen will be administered by SC injection.
Study: NCT04858529
Drug: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
Study: NCT04858529
Drug: investigator-selected taxane/trastuzumab/pertuzumab (THP)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: investigator-selected taxane/trastuzumab/pertuzumab (THP)
Study: NCT04874207
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose adaptation at the beginning of cycle 2 and cycle 3 after regorafenib dosage at day 15
Study: NCT05416320
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
Study: NCT05470725
Drug: CIN-107
Normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 10 mg CIN-107 oral dose (2 X 5 mg tablets).
Study: NCT05690191
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide tablets: 20mg orally, twice a week (at least 3 days between doses
Study: NCT05690191
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsule: 25mg orally, once before going to bed every night, from day 1 to day 21 of each cycle
Study: NCT05690191
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab injection: 375mg/m2 intravenously, once every 4 weeks (Q4w), on the first day of each cycle
Study: NCT06107673
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
Study: NCT06541405
Drug: NK520
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The number of NK520 cell infused for each dosing should be calculated base on the body weight of subject. NK520 will be administered through intravenous infusion.
Study: NCT06107673
Drug: Docetaxel injection
Normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study: NCT06107673
Drug: Epirubicin Hydrochloride Injection
Normalized name: Epirubicin Hydrochloride Injection
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study: NCT04887038
Drug: SRT-015
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each study part (A,B and C) will be completed sequentially, but with partial overlapping. The first cohort of Part B (Cohort B1) may be initiated after safety, tolerability and available PK data are assessed and deemed suitable to continue for a single dose on Part A that is equal to or greater than the total exposure of cohort B1. Part C (Cohort C1 \& C2) may be initiated after safety, tolerability and PK data are assessed and deemed suitable to continue for a single dose in part A that is at least double the specified dose from part C.
Study: NCT05877664
Drug: ZG0895 Hydrochloride for Injection
Normalized name: terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
Study: NCT03196934
Drug: Cannabidiol oral solution
Normalized name: cannabidiol Oral Solution
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol; Pharmacological class of drug
Study: NCT06274437
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT06274437
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT05488353
Drug: Disitamab Vedotin for Injection,Penpulimab Injection
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
Study: NCT05524532
Drug: Immulina TM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiiating properties.
Study: NCT06377085
Drug: 5-Azacytidine 10mg/m^2
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Azacytidine 10mg/m\^2, one-time subcutaneous injection
Study: NCT06377085
Drug: 5-Azacytidine 20mg/m^2
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Azacytidine 20mg/m\^2, one-time subcutaneous injection
Study: NCT06377085
Drug: 5-Azacytidine 35mg/m^2
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Azacytidine 35mg/m\^2, one-time subcutaneous injection
Study: NCT06377085
Drug: 5-Azacytidine 75mg/m^2
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Azacytidine 75mg/m\^2, one-time subcutaneous injection
Study: NCT04730375
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation
Study: NCT05089175
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FIGO adopts and supports that in high-risk women, defined by the first-trimester combined test, aspirin \~150 mg/night should be commenced at 11-14+6 weeks of gestation until either 36 weeks of gestation, when delivery occurs, or when pre-eclampsia is diagnosed.
Study: NCT04983498
Drug: Ondansetron 4 MG
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis.
Study: NCT04323566
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)
Study: NCT00002370
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05638984
Drug: Decitabine Injection
Normalized name: decitabine Injection
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection site citabine, 10 mg/ bottle, 10 mg/d, Q3W, D1-D5 intravenous infusion; Tirelizumab injection 200mg D5 intravenous infusion
Study: NCT05638984
Drug: tirelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10ml: 100mg / 1 bottle, 200mg, Q3W, D1 i. v. infusion.
Study: NCT05128344
Drug: AMZ002 injectable solution, 0.5mg/mL
DrugBank: AMZ002 (DB17017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable solution
Study: NCT05128344
Drug: Vigabatrin, oral
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04972175
Drug: 50-Hour Intervention - Rapid Insulin lispro
Normalized name: insulin lispro 50 UNT/ML
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous-delivery of insulin lispro using pump therapy.
Study: NCT04891653
Drug: BR790
Normalized name: Bremelanotide
DrugBank: Bremelanotide (DB11653)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive oral administration of BR790.
Study: NCT03640377
Drug: Praziquantel
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel given as crushed tablets (40 or 80 mg/kg)
Study: NCT06305546
Drug: Chlorhexidine Gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
Study: NCT06305546
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
Study: NCT06305546
Drug: combination gel (chlorhexidine and metronidazole)
Normalized name: chlorhexidine / metronidazole
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
Study: NCT05396781
Drug: Proflavine
Normalized name: proflavine
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.
Study: NCT06539559
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Based on the results of STUDY301 and STUDY304, eribulin showed outstanding therapeutic effect and tolerable adverse events in patients with metastatic breast cancer
Study: NCT05586100
Drug: Toripalimab+cetuximab
Normalized name: Toripalimab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Toripalimab administered by intravenous drip at a fixed dose of 240 mg for subjects weighing \<50 kg at baseline, using 3 mg/kg. administered every 3 weeks, 2 preoperative and 6 postoperative doses.~The starting dose of cetuximab is 400 mg/m2, with a titration time of 120 min, and the titration rate should be controlled within 5 ml/min. The maintenance dose is 250 mg/m2 administered weekly for a total of 6 preoperative doses; patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional 6 cycles of postoperative cetuximab adjuvant therapy.
Study: NCT00483392
Drug: metformin, rosiglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05231941
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus and infusion of lidocaine will be administered
Study: NCT05231941
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bilateral TAP block will be given to these patients
Study: NCT05431907
Drug: Allocetra-OTS
Normalized name: Allocetra
DrugBank: Allocetra (DB16424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Study: NCT05810142
Drug: furquimatinib and sintilimab
Normalized name: cytarabine and daunorubicin
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: furquimatinib and sintilimab
Study: NCT05954988
Drug: LTI-03
Normalized name: LTI-03
DrugBank: LTI-03 (DB18491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caveolin-1-Scaffolding-Protein-Derived Peptide
Study: NCT05882903
Drug: Betamethasone Dipropionate Nasal Cream 0.0644%
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone Dipropionate Nasal Cream 0.0644% is applied topically to the inflamed tissue of the sinus using a pre-filled syringe and applicator under the guidance of an endoscope. Up to 5g on each side of the sinus (10g in total).
Study: NCT05945732
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a non-interventional study and medication will be administered according to the SmPC as local standard of care and as part of the routine clinical practice.~Trastuzumab (T-DXd) to be administered according to the SmPC.~Conventional therapy (eg. capecitabine, eribulin, gemcitabine, paclitaxel, nab paclitaxel) to be administered according to the SmPC.
Study: NCT05760677
Drug: pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: the pioglitazone group： classic treatment: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone
Study: NCT05760677
Drug: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar (32mg QD)
Study: NCT06539559
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study E2100, AVADO and RIBBON-1 found that in the first-line chemotherapy for advanced breast cancer, the addition of bevacizumab can significantly improve the efficacy of traditional chemotherapy drugs. Study RIBBON-2 and TANIA have confirmed the effectiveness of bevacizumab in the second and third line treatment of advanced HER2 negative breast cancer. Compared with chemotherapy alone, the addition of bevacizumab can prolong the PFS by 0.6 to 2.1 months.
Study: NCT05235256
Drug: lidocaine plus dexamethasone
Normalized name: dexamethasone / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine plus dexamethasone
Study: NCT04745988
Drug: Lenvatinib 20mg
Normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
Study: NCT04745988
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Study: NCT04745988
Drug: Lenvatinib 8mg
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
Study: NCT04745988
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.
Study: NCT04745988
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.
Study: NCT04745988
Drug: Levofolinate
Normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.
Study: NCT03575000
Drug: Bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
Study: NCT04630886
Drug: Tranexamic acid injection
Normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection of 50mg/ml TXA
Study: NCT04491383
Drug: Tocovid Suprabio (HOV-12020)
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol
Study: NCT04851015
Drug: trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/kg/day of TMP component
Study: NCT04851015
Drug: trimethoprim-sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/kg/day of TMP component
Study: NCT06240143
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intradermal
Study: NCT06240143
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intradermal
Study: NCT06240143
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravenous
Study: NCT04836910
Drug: Oral contraceptive pills
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal treatment
Study: NCT04836910
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin resistance treatment
Study: NCT05454956
Drug: TP-03
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day in participants in the BID dosing arm and three times a day in participants in the TID dosing arm
Study: NCT05454956
Drug: TP-03 Vehicle
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle of TP-03 ophthalmic solution, administered once a day in participants in the BID dosing arm to maintain masking between arms
Study: NCT05447078
Drug: Immulina TM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study: NCT02545127
Drug: Merotocin
Normalized name: Merotocin
DrugBank: Merotocin (DB12932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Study: NCT05897554
Drug: intra-arterial alteplase
Normalized name: methotrexate
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For patients in the successful MT plus intra-arterial alteplase group, after successful recanalization, neurointerventionalists administered intra-arterial thrombolysis with alteplase according to protocol. The angiographic scores will be assessed immediately after intra-arterial thrombolysis.
Study: NCT05040464
Drug: MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg SC once a week
Study: NCT05575427
Drug: Levofloxacin or Cotrimoxazole
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will receive levofloxacin or cotrimoxazole oral between 7-28 days
Study: NCT05244577
Drug: Olanzapine Tablets
Normalized name: Olanzapine Tablets
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine,Ondansetron,Dexamethasone,Fosaprepitant
Study: NCT06476821
Drug: BMS-986435
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05946772
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5mg/kg body weight Cyclosporine A as an intravenous bolus
Study: NCT05333744
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
Study: NCT04919551
Drug: vicagrel
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration after fasting/high-fat meal/low-fat meal
Study: NCT05829317
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Magnesium sulfate